Neoantigen-based Personalized Cancer therapeutic Vaccines pipeline
Drugs:-
And many others
Key Players:-
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Neoantigen-based Personalized Cancer therapeutic Vaccines
3. Competitive Intelligence Analysis for Neoantigen-based Personalized Cancer therapeutic Vaccines
4. Neoantigen-based Personalized Cancer therapeutic Vaccines: Market Overview at a Glance
4.1. Neoantigen-based Personalized Cancer therapeutic Vaccines-Region Wise Total Market Share (%) Distribution by 2035
4.2. Neoantigen-based Personalized Cancer therapeutic Vaccines-Indication Wise Total Market Share (%) Distribution by 2035
5. Neoantigen-based Personalized Cancer therapeutic Vaccines
5.1. Introduction
5.1.1. Tumor neoantigens: from basic research to clinical applications
5.1.2. Historical overview in the understanding of tumor neoantigens
5.1.3. Neoantigens-directed immunoediting and immune escape
5.1.4. Overview of Preclinical and clinical neoantigen vaccine-based studies
5.1.4.1. Neoantigen-based adoptive T cell transfer
5.1.4.2. Neoantigen-based cancer vaccines
5.1.4.3. Combination of neoantigen vaccine with other therapies
5.1.4.3.1. Biomarker for immune checkpoint inhibitors
5.1.4.3.2. Resistance mechanism for immune checkpoint inhibitors
5.1.5. Identification and prediction of neoantigens
5.1.6. Principle of neoantigen vaccines
5.1.7. Clinical progress
5.1.8. Pros and Cons
6. Unmet Needs
7. Emerging Therapies
7.1. Key Cross Competition
7.2. Tedopi (OSE2101): OSE Immunotherapeutics
7.2.1. Product Description
7.2.2. Other Developmental Activities
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. GRANITE (GRT-C901) + SLATE (GRT-R902): Gritstone Oncology
7.3.1. Product Description
7.3.2. Other Developmental Activities
7.3.3. Clinical Development
7.3.4. Safety and Efficacy
7.3.5. Product Profile
7.4. GEN-009 Adjuvanted Vaccine: Genocea Biosciences
7.4.1. Product Description
7.4.2. Other Developmental Activities
7.4.3. Clinical Development
7.4.4. Safety and Efficacy
7.4.5. Product Profile
7.5. TG01 Vaccine: Targovax
7.5.1. Product Description
7.5.2. Other Developmental Activities
7.5.3. Clinical Development
7.5.4. Safety and Efficacy
7.5.5. Product Profile
7.6. iNeo-Vac-P01: Hangzhou Neoantigen Therapeutics
7.6.1. Product Description
7.6.2. Other Developmental Activities
7.6.3. Clinical Development
7.6.4. Safety and Efficacy
7.6.5. Product Profile
7.7. NEO-PV-01: Neon Therapeutics
7.7.1. Product Description
7.7.2. Other Developmental Activities
7.7.3. Clinical Development
7.7.4. Safety and Efficacy
7.7.5. Product Profile
List to be continued in report…
8. Neoantigen-based Personalized Cancer therapeutic Vaccines: Seven Major Market Analysis
8.1. Key Findings
8.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size in 7MM
9. 7MM: Market Outlook
9.1. United States: Market Size
9.1.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in the United States
9.1.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in the United States
9.2. EU-5 countries: Market Size and Outlook
9.2.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in EU5 Countries
9.2.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in EU5 Countries
9.3. Japan Market Outlook
9.3.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in Japan
9.3.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in Japan
10. Attribute analysis
11. KOL Views
12. Market Drivers
13. Market Barriers
14. Future Outlook
15. Appendix
15.1. Bibliography
15.2. Report Methodology
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/